Retrospective Study Finds Pulmonary Fibrosis in Patients with Severe COVID-19

A retrospective cohort study has identified a notable prevalence of pulmonary fibrosis among patients who experienced severe cases of COVID-19. The findings highlight the potential long-term respiratory complications associated with critical illness caused by the virus.

The study examined medical records of individuals who were critically ill with COVID-19, focusing on those who required intensive care or prolonged hospitalization. Researchers observed that many of these patients developed pulmonary fibrosis, a condition characterized by scarring and stiffening of lung tissue that can lead to breathing difficulties and reduced oxygen exchange. The results underscore the importance of addressing this risk in post-COVID care strategies and may prompt further investigation into preventive measures and treatment options for affected individuals.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: October 3, 2025

Related posts:

Russia’s Pharmaceutical Market Projected to Reach $25 Billion by 2025 Mercalis and PharmaCord Merge to Form Valeris Focused on Life Sciences Therapy Delivery Brii Biosciences Partners with Joincare Pharmaceutical for Licensing and Development of BRII-693 to Combat Drug-Resistant Infections Access Infinity Launches AI-Powered Market Access Solution on Nuro Platform

Author

Mark Chiang